Sugi Predict

Sugi Predict / Compounds / SCHEMBL6034692

SCHEMBL6034692

SCHEMBL6034692

O=[N+]([O-])c1ccc(-n2cncn2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FBP1 P09467 1/20 0.60
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ KDM4E B2RXH2 1/20 0.56
▸ ALDH1A1 P00352 1/20 0.56
▸ HTT P42858 2/20 0.50
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ MAPT P10636 3/20 0.43
▸ CYP2A6 P11509 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ HSP90AA1 P07900 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5963002 0.91 FBP1 (0.52) FBP1SMN1; SMN2KDM4EALDH1A1HTT
SCHEMBL6321742 0.89 L3MBTL1 (0.56) FBP1SMN1; SMN2KDM4EALDH1A1MAPT
1,2,4-Triazole SCHEMBL9273703 0.86 FBP1 (0.48) FBP1SMN1; SMN2KDM4EALDH1A1HTT
SCHEMBL4456339 0.80 KEAP1 (0.51) FBP1SMN1; SMN2KDM4EALDH1A1HTT
SCHEMBL27905069 0.80 SMN1; SMN2 (0.72) FBP1SMN1; SMN2KDM4EALDH1A1HTT
SCHEMBL15156883 0.78 FBP1 (0.49) FBP1SMN1; SMN2KDM4EALDH1A1MAPT
SCHEMBL9113748 0.77 MAPT (0.53) FBP1KDM4EALDH1A1HTTCYP1A2
SCHEMBL2357244 0.76 MAPT (0.46) FBP1SMN1; SMN2KDM4EALDH1A1HTT
SCHEMBL5535834 0.75 SMN1; SMN2 (0.66) FBP1SMN1; SMN2KDM4EALDH1A1HTT
SCHEMBL4764865 0.74 HPGD (0.51) FBP1SMN1; SMN2KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154115-A1 ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2025-05-15 — — US disclosed
CN-119137106-A Arylbenzisoxazole compounds as IP6K and IPMK inhibitors and methods of use thereof 北卡罗来纳查佩尔山大学 2024-12-13 — — CN disclosed
US-20190151312-A1 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. 2019-05-23 — — US disclosed
US-9745320-B2 Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) 2017-08-29 — — US disclosed
US-9745320-B2 Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) 2017-08-29 — — US disclosed
EP-3204009-A1 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES BioMarin Pharmaceutical Inc. (US) 2017-08-16 — — EP disclosed
WO-2016057834-A9 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. (US) 2017-04-13 — — WO disclosed
WO-2016057834-A9 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. (US) 2017-04-13 — — WO disclosed
WO-2016073652-A1 IMINOSUGARS USEFUL FOR THE TREATMENT OF VIRAL DISEASES UNITHER VIROLOGY, LLC (US) 2016-05-12 — — WO disclosed
WO-2016057834-A1 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. (US) 2016-04-14 — — WO disclosed
EP-0733048-A1 HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1996-09-25 — — EP disclosed
US-5510362-A VASOCONSTRUCTION MERCK, SHARP AND DOHME LIMITED (GB) 1996-04-23 — — US disclosed
US-5508422-A USEFUL AS CATALYSTS IN FORMING CONDENSATION PRODUCTS OF FORMALDEHYDE BASF AKTIENGESELLSCHAFT (DE) 1996-04-16 — — US disclosed
WO-1996002484-A1 METHOD OF PRODUCING ACYLOINES BASF AKTIENGESELLSCHAFT (DE) 1996-02-01 — — WO disclosed
WO-1995015954-A1 HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1995-06-15 — — WO disclosed
US-5386062-A Triazole or tetrazole compounds BASF AKTIENGESELLSCHAFT (DE) 1995-01-31 — — US disclosed
EP-0630374-A1 IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES MERCK SHARP & DOHME LTD. (GB) 1994-12-28 — — EP disclosed
EP-0587044-A2 Method for the catalytic production of formaldehyde condensation products BASF Aktiengesellschaft (DE) 1994-03-16 — — EP disclosed
WO-1994002477-A1 IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 1994-02-03 — — WO disclosed
WO-1993018029-A1 IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 1993-09-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190151312-A1 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES HPSE, GAA, MAN2B1 FBP1 127/4885SMN1; SMN2 991/4885KDM4E 3788/4885
US-20250154115-A1 ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF PFKL, IP6K2, IP6K1 FBP1 56/4885SMN1; SMN2 4503/4885KDM4E 1223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.